Shopping Cart
Remove All
Your shopping cart is currently empty
Tadocizumab
(Synonyms: YM-337, YM337, C4G1, C4G 1) Copy Product Info
🥰Excellent
Synonyms: YM-337, YM337, C4G1, C4G 1
Catalog No. T76979 Copy Product Info
🥰Excellent
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
Tadocizumab
Cas No. 339086-80-5
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $289 | In Stock | In Stock | |
| 5 mg | $723 | In Stock | In Stock | |
| 10 mg | $986 | - | In Stock | |
| 25 mg | $1,490 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.1% (SDS-PAGE); 97.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease. |
| In vitro | Tadocizumab significantly inhibited ADP-induced platelet aggregation in vitro and completely blocked arachidonic acid-induced platelet aggregation. [1] Tadocizumab also inhibited human platelet adhesion to von Willebrand factor, fibrinogen, fibronectin, and subendothelial matrix. [2] |
| In vivo | Tadocizumab inhibits platelet aggregation in vitro in a dose-dependent manner. In rhesus monkeys, platelet aggregation was completely prevented by intravenous injection over 0.25 mg/kg or at an infusion rate of 1.5 μg/kg/min. In a photochemically induced thrombosis model in squirrel monkeys, intravenous injection of 1 mg/kg of Tadocizumab followed by a continuous infusion at a rate of 6 μg/kg/min for 60 minutes effectively prevented occlusive thrombosis in experimental monkeys.[1] |
| Synonyms | YM-337, YM337, C4G1, C4G 1 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | Integrin a2b3 (ITGA2 & ITGB3) |
| Molecular Weight | 47.59 kDa |
| Cas No. | 339086-80-5 |
| Isotype | IgG1 |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: Tadocizumab in vivo | Tadocizumab in vitro | Tadocizumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.